Today, the Wall Street Journal published an article by Jonathan D. Rockoff that takes an in-depth look at the actual and expected pricing of biosimilars in the U.S. For those with WSJ subscriptions, it is well worth a read: http://www.wsj.com/articles/knockoffs-of-biotech-drugs-bring-paltry-savings-1462458209.